QBiotics Group Limited

General Information

Company Name

Founded Year

2000

Location (Offices)

Australia +4

Founders / Decision Makers

Number of Employees

Industries

Biotechnology, Health Care

Funding Stage

Social Media

QBiotics Group Limited - Company Profile

QBiotics Group Limited is a biotechnology company specializing in plant-derived, cell signaling small molecules. It is currently focused on oncology and wound healing, aiming to address major health issues for both humans and companion animals.

The company's unique approach involves discovering, developing, and commercializing novel pharmaceuticals based on plant-derived cell-signaling molecules derived from the Australian tropical rainforest, supported by their discovery platform, EcoLogic™. QBiotics simultaneously targets the human and veterinary markets, offering early-to-market veterinary products and leveraging real-world animal data to inform and de-risk their human programs. Presently, the company has two leading programs.

The first program is an oncology drug, tigilanol tiglate, with demonstrated efficacy against various solid tumors. This drug is registered as a veterinary pharmaceutical under the brand name STELFONTA® and is marketed in the US, EU, UK, and Australia. Additionally, it is undergoing human Phase II clinical development. The second program is EBC-1013, a pharmaceutical targeting chronic and acute wound healing. QBiotics boasts a motivated team of 61 employees dedicated to driving these initiatives forward. Founded in 2000, QBiotics operates within the Biotechnology and Health Care industries.

Taxonomy: pharmaceuticals, oncology drug development, wound healing, veterinary pharmaceuticals, cell signalling molecules, plant-derived compounds, clinical development, small molecule drugs, discovery platform, commercialization, solid tumor treatment, intratumoral administration, partnership, animal data